Dawa Ltd. announces Nairobi pharmaceutical plant expansion

By Jonathan Dyble
Share
Leading Kenyan pharmaceutical company, Dawa Ltd., has announced that it will be committing Sh3bn (US$290m) to the construction of a new factory at its c...

Leading Kenyan pharmaceutical company, Dawa Ltd., has announced that it will be committing Sh3bn (US$290m) to the construction of a new factory at its current Nairobi plant.

The investment is evidence of the company’s progress in recent years, having expanded from just 20 employees in 2004 to its current 400.

As part of the announcement, Managing Director of Dawa, Dr Ajay Patel, outlined his hopes that the expanded facility will help the company access a greater number of African markets.

See also:

“Last year we achieved a Sh2 billion turnover up from 2015’s Sh1.8 billion which informs our strategy for expansion. We also plan to enter the Tanzania market via a distribution network that we have now established,” said Dawa Ltd.’s General Manager of Sales and Marketing, Sunil Kumar, who made the announcement alongside Patel.

The pair also announced that the new factory will feature the industry’s latest machinery, allowing the company to launch a new line of new lifetstyle drugs aimed at treating Diabetic, hypertensive and cardiovascular patients.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma